Highlights

• Sanofi India reported FY26 net profit of INR 10,260 lakh.
• The stock gained 0.64% during early trading on June 17.
• Shares remain substantially below their 52-week high level.

Sanofi India Limited (NSE:SANOFI) traded higher on 17 June 2026, rising 0.64% to INR 3,325.00 from its previous close of INR 3,303.70. During the session, the stock touched an intraday high of INR 3,346.00 and a low of INR 3,290.00.

The company operates in the pharmaceutical sector and is engaged in manufacturing and marketing healthcare products in India. While the stock witnessed a modest gain during the latest session, its long-term performance remains significantly below broader market benchmarks.

Recent Gains Contrast With Longer-Term Weakness

Sanofi India's stock performance presents a mixed picture across different periods. Over the last week, the stock advanced 4.67%, outperforming the NIFTY 50's gain of 3.66%. During the past month, the stock rose 3.33%, ahead of the benchmark's return of 1.78%.

However, on a year-to-date basis, the stock declined 18.86%, compared with a 7.96% decline in the NIFTY 50.

The longer-term trend remains weaker. Sanofi India has fallen 45.05% over the last year, while the benchmark declined 3.18%. Over three years, the stock has declined 52.02%, and over five years it has fallen 57.13%, significantly underperforming the broader market.

Trading Activity and Market Capitalisation

The stock recorded trading volume of approximately 0.08 lakh shares, generating traded value of around INR 2.59 crore. Sanofi India currently has a market capitalisation of INR 7,657.68 crore, while its free-float market capitalisation stands at INR 3,016.74 crore.

The stock's impact cost was reported at 0.05, reflecting relatively healthy liquidity. Deliverable quantity accounted for 48.50% of traded volume during the session. Annualised volatility stood at 24.45%, indicating lower price fluctuations compared with many mid-cap stocks.

FY26 Financial Performance

For the period ended 31 March 2026, Sanofi India reported unaudited standalone total income of INR 47,670 lakh. Profit before tax stood at INR 13,790 lakh, while net profit reached INR 10,260 lakh. Earnings per share were reported at INR 44.55.

The results indicate that the company remained profitable during the reporting period despite challenging stock market performance over the past year. Investors generally monitor pharmaceutical companies based on product portfolio performance, regulatory developments, pricing trends and market demand.

Valuation Metrics in Focus

Sanofi India is currently trading at a reported price-to-earnings ratio of 24.56, while the adjusted P/E ratio stands at 23.14.

Valuation remains an important consideration for pharmaceutical stocks, particularly as investors assess earnings visibility, product mix and sector-specific growth drivers.

Trading Near the Lower End of Annual Range

The stock touched a 52-week high of INR 6,410.00 on 30 June 2025 and a 52-week low of INR 3,054.00 on 29 May 2026. At the current market price of INR 3,325.00, Sanofi India is trading much closer to its annual low than its yearly high.

Although the stock has recovered from the recent low, it remains substantially below levels seen a year ago. The difference between the current price and the 52-week high highlights the magnitude of the correction experienced during the past twelve months.

Pharmaceutical Sector Remains Closely Watched

The pharmaceutical industry is influenced by regulatory approvals, product demand, healthcare spending, competition and pricing policies. Companies operating in this sector are also affected by changes in raw material costs, compliance requirements and product launches. These factors can influence both revenue growth and profitability.

As healthcare demand continues to evolve, investors remain focused on earnings trends and operational performance across the sector.

Bull Case

Sanofi India reported FY26 net profit of INR 10,260 lakh and earnings per share of INR 44.55. The stock has also outperformed the NIFTY 50 over the past week and month.

Bear Case

The stock has declined 45.05% over the past year and remains significantly below its 52-week high. Long-term returns over three and five years remain negative.

Key Risks

• Regulatory changes may affect product approvals.
• Pricing pressures could impact profitability.
• Competition may influence market share.
• Product concentration risks may affect earnings.

Summary

Sanofi India reported unaudited standalone net profit of INR 10,260 lakh and earnings per share of INR 44.55 for the period ended March 2026. While the stock has outperformed the NIFTY 50 over the past week and month, its longer-term returns remain negative. Trading at INR 3,325.00, the stock remains closer to its 52-week low than its annual high, reflecting the correction seen during the past year.

FAQs

Q: What was Sanofi India's net profit for the latest reported period?
A: Sanofi India reported standalone net profit of INR 10,260 lakh for the period ended March 2026.

Q: What is Sanofi India's current P/E ratio?
A: The stock is trading at a reported price-to-earnings ratio of 24.56.

Q: How has Sanofi India performed over the last year?
A: The stock has declined approximately 45.05% over the past one-year period.